Illumina, Inc. $ILMN Shares Acquired by Ethic Inc.

Ethic Inc. lifted its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 23.1% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 16,678 shares of the life sciences company’s stock after purchasing an additional 3,125 shares during the quarter. Ethic Inc.’s holdings in Illumina were worth $1,581,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Rise Advisors LLC grew its stake in shares of Illumina by 173.6% during the 1st quarter. Rise Advisors LLC now owns 353 shares of the life sciences company’s stock worth $28,000 after purchasing an additional 224 shares during the period. Cullen Frost Bankers Inc. acquired a new position in shares of Illumina during the 2nd quarter worth $41,000. Golden State Wealth Management LLC grew its stake in shares of Illumina by 123.2% during the 1st quarter. Golden State Wealth Management LLC now owns 529 shares of the life sciences company’s stock worth $42,000 after purchasing an additional 292 shares during the period. Caitong International Asset Management Co. Ltd grew its stake in shares of Illumina by 2,936.8% during the 1st quarter. Caitong International Asset Management Co. Ltd now owns 577 shares of the life sciences company’s stock worth $46,000 after purchasing an additional 558 shares during the period. Finally, WPG Advisers LLC acquired a new position in shares of Illumina during the 1st quarter worth $58,000. 89.42% of the stock is owned by institutional investors and hedge funds.

Illumina Price Performance

NASDAQ:ILMN opened at $100.11 on Friday. The firm has a market cap of $15.39 billion, a price-to-earnings ratio of 12.67, a price-to-earnings-growth ratio of 2.47 and a beta of 1.40. The company has a current ratio of 1.81, a quick ratio of 1.41 and a debt-to-equity ratio of 0.66. The company’s 50-day moving average is $98.17 and its two-hundred day moving average is $91.65. Illumina, Inc. has a 12-month low of $68.70 and a 12-month high of $156.66.

Illumina (NASDAQ:ILMN) last released its earnings results on Thursday, July 31st. The life sciences company reported $1.19 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.02 by $0.17. Illumina had a net margin of 29.36% and a return on equity of 28.93%. The company had revenue of $1.06 billion for the quarter, compared to analyst estimates of $1.12 billion. During the same period in the prior year, the firm earned $0.36 EPS. The firm’s quarterly revenue was down 4.8% on a year-over-year basis. Illumina has set its FY 2025 guidance at 4.450-4.55 EPS. Research analysts expect that Illumina, Inc. will post 4.51 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on ILMN shares. Evercore ISI lowered their price target on shares of Illumina from $135.00 to $132.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 7th. Robert W. Baird set a $105.00 price objective on shares of Illumina in a research report on Friday. Morgan Stanley boosted their price objective on shares of Illumina from $100.00 to $105.00 and gave the stock an “equal weight” rating in a research report on Monday, August 4th. Canaccord Genuity Group boosted their price objective on shares of Illumina from $99.00 to $105.00 and gave the stock a “hold” rating in a research report on Friday, August 1st. Finally, Citigroup lowered shares of Illumina from a “hold” rating to a “strong sell” rating and decreased their price objective for the stock from $85.00 to $80.00 in a research report on Wednesday, July 9th. Five analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and three have given a Sell rating to the company’s stock. According to data from MarketBeat.com, Illumina currently has an average rating of “Hold” and an average price target of $115.25.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.